Skip to content

Advertisement

  • Research
  • Open Access

Detection of Malawi polyomavirus sequences in secondary lymphoid tissues from Italian healthy children: a transient site of infection

Virology Journal201613:97

https://doi.org/10.1186/s12985-016-0553-z

Received: 2 February 2016

Accepted: 1 June 2016

Published: 10 June 2016

Abstract

Background

The novel Malawi polyomavirus (MWPyV) was initially detected in stool specimens from healthy children and children with gastrointestinal symptoms, mostly diarrhea, indicating that MWPyV might play a role in human gastroenteric diseases. Recently, MWPyV sequences were additionally identified in respiratory secretions from both healthy and acutely ill children suggesting that MWPyV may have a tropism for different human tissues. This study was designed to investigate the possible sites of latency/persistence for MWPyV in a cohort of healthy Italian children.

Methods

Specimens (n° 500) of tonsils, adenoids, blood, urines and feces, from 200 healthy and immunocompetent children (age range: 1–15 years) were tested for the amplification of the MWPyV LT antigen sequence by quantitative real-time PCR. Samples (n° 80) of blood and urines from 40 age-matched children with autoimmune diseases, were screened for comparison. Polyomaviruses JC/BK and Epstein-Barr Virus (EBV) were also tested as markers of infection in all samples using the same molecular technique.

Results

In our series of healthy children, MWPyV was detected only in the lymphoid tissues showing a prevalence of 6 % in tonsils and 1 % in adenoids, although with a low viral load. No JCPyV or BKPyV co-infection was found in MWPyV positive samples, while EBV showed a similar percentage of both in tonsils and adenoids (38 and 37 %).

Conversely, no MWPyV DNA was detected in stool from babies with gastroenteric syndrome. With regards to autoimmune children, neither MWPyV nor BKPyV were detected in blood, while JCPyV viremia was observed in 15 % (6/40) of children treated with Infliximab. Urinary BKPyV shedding was observed in 12.5 % (5/40) while JCPyV in 100 % of the samples.

Conclusions

The detection of MWPyV sequences in tonsils and adenoids of healthy children suggests that secondary lymphoid tissues can harbour MWPyV probably as transient sites of persistence rather than actual sites of latency.

Keywords

  • Malawi infection
  • Children
  • Lymphoid tissues
  • Route of transmission
  • Sites of persistence

Background

The family of human polyomaviruses (PyVs), a group of small DNA viruses, has recently grown to include 13 members, raising the question of their potential role in humans, with and without manifest diseases [14].

PyVs seem to be harmless in immunocompetent individuals, but they can cause diseases in immunocompromised patients. The etiological role in human diseases has been established for 4 of the 13 human polyomaviruses, including tumors without productive viral replication and non-neoplastic productive viral infections.

The known human polyomaviruses BKPyV and JCPyV, display potential tumorigenic characteristics, although their role in human cancers remains controversial [57]. The only human PyV to have been recognized as potential oncovirus is the recently discovered Merkel cell polyomavirus (MCPyV), which seems to be a causal factor in Merkel cell carcinoma, an aggressive skin malignancy [811]. On the other hand, BKPyV, but also JCPyV, is associated with polyomavirus nephropathy (PVAN) in renal transplant recipients, and BKPyV is also associated with hemorrhagic cystitis in bone marrow transplant patients, kidney allograft dysfunction and potential graft loss [1215]. JCPyV is the etiological agent of progressive multifocal leukoencephalopathy (PML) [16, 17], while the Trichodysplasia Spinulosa-associated polyomavirus (TSPyV) is thought to be the etiological agent of trichodysplasia spinulosa, also known as pylomatrix dysplasia, a rare skin disease characterized by the development of follicular papules and keratin spines [1820].

Nothing is known on the possible role in human diseases of the newly discovered polyomaviruses WUPyV and KIPyV, the Saint Louis polyomavirus (STLPyV), the Malawi polyomavirus (MWPyV), the Human polyomavirus 12 (HPyV12) and the New Jersey polyomavirus (NJPyV),which have been detected in different human biological samples including naso-pharyngeal secretions [2124], stool [25, 26], liver and vascular endothelial cells [4, 27]. However, HPyVs have been proposed as candidate causative factors in a number of diseases with unknown etiology. For instance, the association between these novel polyomaviruses and the primary mucosal melanomas has recently been investigated, albeit without significant results [28].

PyVs are ubiquitous viruses in the human population, with no less than 20 %, and up to 90 %, of the adult population carrying antibodies against these viruses, depending on the PyV strains, the geographic area and on the demographic characteristics of the study cohorts [2931].

For almost all the members of the PyVs family, the route of intra-human transmission is still unknown. However, strong evidence indicates that JCPyV and BKPyV can establish latency in the genitourinary tract [32, 33], since episodes of self-limiting asymptomatic reactivation by intermittent urinary shedding or viremia can occur during severely impaired immune surveillance [34]. Nevertheless, other organ niches such as the gastroenteric trait [35], the lymphoid tissues [36, 37] and the central nervous system [3841] have also been suggested as potential sites of latency.

The secondary lymphoid tissue has been proposed as a possible site of persistence for WUPyV, KIPyV and TSPyV by some authors, [4244]. Moreover, MWPyV and STLPyV sequences were recently detected in 2 % of tonsillar swabs from children with chronic tonsillar disease, raising the question of how the lymphoid system may play a role in human polyomavirus infection and persistence [45].

Among new Polyomaviruses, particular attention has been dedicated, in Italy, to the Malawi polyomavirus since a sero-epidemiological survey on a large sample of subjects (from 1 to ≥ 80 years old), has documented the circulation of this virus with a trend of frequency similar to that reported for the human polyomaviruses JC and BK. Specifically, MWPyV seroconversion was shown to occur early in childhood, with 26.9 % of 1- to 2-year-old children testing seropositive, although seropositivity peaked (68.2 %) in 3- to 4-year-old children [46].

MWPyV was initially identified by shotgun pyrosequencing of DNA extracted from virus-like particles isolated from a stool sample collected from a healthy child in Malawi. MWPyV is an unenveloped icosahedral virion containing a small, closed circular double-strand DNA genome of 4927 bp. The complete DNA sequencing showed a MWPyV genome structure typical of the Polyomaviridae family, divided into three regions: the regulatory region, the early region and the late region. The early region encodes the large T antigen (LTAg) and small T antigen (STAg), while the late region is expressed after viral replication and encodes the structural proteins of the capsid VP1, VP2, VP3. The regulatory region contains the origin of replication and the promoter genes for transcription of the early and late regions [25].

Following, MWPyP was found in 2.3 % of fecal samples from patients with gastrointestinal diseases [25]. Subsequently, a novel highly divergent polyomavirus, provisionally named MXPyV, was identified by deep sequencing from diarrheal stool samples in Mexico. The whole-genome sequence of MXPyV was found to be nearly identical to that of polyomaviruses MWPyV and HPyV10, indicating that these three viruses are different variants of the same species [47]. The detection of MWPyV in stool of children with diarrhea, often without known etiology, raised the hypothesis that MWPyV might play a role in human gastroenteric diseases. It is also possible, however, that MWPyV has a tropism for other human tissues and is shed in stool as a mode of intra-human transmission [48]. Conversely, Rockett et al. reported the presence of MWPyV in respiratory secretions from acutely ill patients and in babies (<18 months old) with mild upper respiratory symptoms [49]. Therefore, the question of which virus excretion route drives human infection has not, as yet, been fully resolved.

One of the key points that need to be explored is whether MWPyV is a pathogen of humans, and if so what diseases are associated with its infection, or rather an environmental contaminant that transiently infects humans.

The present study was designed to investigate the site of latency/persistence of MWPyV in healthy children. Tonsil, adenoid, blood, urine and stool specimens from age-matched Italian healthy and immunocompetent children and from children with autoimmune disorders, were screened for this purpose.

JCPyV and BKPyV, which are known to be present with a high number of excreted virions in the urine and feces of immunocompromised subjects [33, 35] and EBV considered a lymphotropic virus, were also tested as markers of infection.

Methods

Subjects and samples

The demographic and clinical characteristics of 240 Italian Caucasian children (200 immunocompetent (healthy) children and 40 autoimmune children) of both sexes, aged 1 to 15 years and referred to the Pediatric Department of the Children’s Hospital “Burlo Garofolo” in Trieste, Italy, are detailed in Table 1.
Table 1

Main demographic and clinical characteristics of children cohorts

Healthy subjects

No. 200

Group 1

No. 100

 Age in years, mean

5.4

  Age categories, number (percentage)

 

  1–5 y

59 (59 %)

  6–15 y

41 (41 %)

  Female, number (percentage)

43 (43 %)

 Diagnosis, number (percentage)

 

  Tonsils/ Adenoids hypertrophy

100 (100 %)

Group 2a

No. 100

  Age in years, mean

1.9

  Age categories, number (percentage)

 

  0–4 y

100 (100 %)

  Female, number (percentage)

70 (70 %)

 Diagnosis, number (percentage)

 

  Enterovirus

10 (10 %)

  Norovirus

20 (20 %)

Autoimmune children

No. 40

  Age in years, mean

8.5

  Age categories, number (percentage)

 

  1–5 y

11 (27.5 %)

  6–15 y

29 (72.5 %)

  Female, number (percentage)

23 (57.5 %)

  Diagnosis, number (percentage)

 

  Crohn Disease

13 (32.5 %)

  Juvenile Rheumatoid Arthritis (JRA)

20 (50.0 %)

  Ulcerative Rectocolitis

7 (17.5 %)

aGastrointestinal disorder children

Among the healthy children, group 1 consisted of 59 children aged 1 to 5 years old, and 41 children aged 6 to 15 years old (mean age of group 1: 5.4 years). These subjects had undergone adeno-tonsillar surgery for hypertrophy of adenoids, defined as adenoids occupying over 80 % of the choanal space, and tonsils graded three (30/100) or four (70/100), according to Brodsky’s classification [50]. Four-hundred matched biological samples, including blood, urine, tonsil and adenoid tissues, were collected from these children.

Group 2, consisted of 100 healthy babies (mean age: 1.9 years; age range: 0–4 years old) affected by acute gastrointestinal pain and diarrhea. By the routine microbiological analysis, ten percent of these children tested positive for Enterovirus (10/100), 20 % for Norovirus (20/100), but all samples resulted negative for other gastrointestinal viruses including Rotavirus, Adenovirus, and Astrovirus.

The 40 autoimmune children (mean age: 8.5 years) included 11 aged 1 to 5 years old, and 29 aged 6–15 years old. These children were affected by inflammatory diseases including Crohn’s disease (13/40), Ulcerative Rectocolitis (7/40) and Juvenile Rheumatoid Arthritis (20/40). Twenty of them had been treated with biological drug monotherapy (Infliximab) because they were refractory to standard pharmacological treatment, but were clinically well at the time of sample collection (blood and urine).

Sample processing and DNA extraction

Upon arrival in the laboratory, all specimens were processed for DNA automated extraction. Twenty mg of fresh tissue from tonsils and adenoids were diced into small pieces, suspended for digestion in a mixture composed by 400 μL of easyMAG lysis buffer (bioMérieux, France) and 40 μL of proteinase K (200 μg/mL), and incubated at 56 °C overnight. Stool specimens were dissolved in sterile water, vortexed and clarified by centrifugation at 6000 g for 10 min (min), and the supernatant recovered for extraction. Total available urines were collected in a 50 mL tube, centrifuged at 4500 g for 20 min and the pellet suspended in sterile water. Whole EDTA blood (100 μL) was diluted in easyMAG lysis buffer (900 μL) at room temperature for 10 min before extraction.

DNA isolation was performed using the NucliSenseasyMAG platform (bioMérieux, France), according to the manufacturer’s protocol. DNA was eluted to a final volume of 50 μL and stored at −80 °C until analysis.

Virological molecular detection

Quantitative real-time PCR (qPCR) assay was performed, using TaqMan chemistry, to detect Malawi polyomavirus, employing the AB PRISM 7500 Sequence Detection System (Applied Biosystem, Milan, Italy). The specific primer pairs were designed to detect the viral large T protein as previously described [25]. Serial 10-fold dilutions ranging from 109 to100 copies of a positive control plasmid (plasmid K-p31, Addgene, USA) were performed to generate standard curves. Briefly, the total 25 μL PCR mixture was composed by 5 μL of extracted nucleic acid, 1 X universal TaqMan real-time PCR master mix (Applied Biosystem), 12.5 pmol of each primer and 4 pmol of the probe. The cycling conditions were: 50 °C for 2 min, 95 °C for 10 min and 45 cycles of 95 °C for 15 s followed by 60 °C for 1 min. A negative control (containing water instead of DNA templates) and one dilution of the plasmid as positive control were added to each run. Based on the standard curve, the MWPyV assay demonstrated a reliable detection limit of approximately five copies per reaction, yielded a linear regression R2 value of 0.99, and was 93 % efficient.

Multiplex TaqMan qPCR was also performed on the same samples to measure the viral loads of JCPyV and BKPyV and to simultaneously amplify the reference human cellular β-globin gene in order to determine the cell equivalents present in each sample and then to calculate the proportion of infected cells (Euro-RT Polyoma Panel kit; Eurospital Spa, Trieste, Italy). In addition, in lymphoid organs, human Epstein-Barr Virus (EBV), used as reference lymphotropic virus, was assayed by specific qPCR with TaqMan chemistry, using commercially available kits (Nanogen, Turin, Italy) according to manufacturer’s recommendations [51].

Finally, enteroviral-pathogens detection was performed using a commercially available kit for Enterovirus (Elite MGB Kit, Elitech Group, Puteaux, France), and by a qualitative EIA test (enzyme immunoassay) (Ridascreen, R-Biopharm, Darmstadt, Germany) for Norovirus, Adenovirus, Astrovirus and Rotavirus, following the supplier’s recommendations.

Statistical analysis

The statistical analysis was performed using IBM SPSS Statistics 20. Fisher Exact Test was used to compare the frequencies of discrete variables. A P value ≤ 0.05 was considered as the threshold of statistical significance.

Results

Human polyomaviruses detection

In this series of children, the overall prevalence of MWPyV was 2.9 % (7/240). The infection was detected only in the healthy/immunocompetent cohort (mean age 6.8 years) where it reached a prevalence of 3.5 % (7/200). No difference according to gender was observed (p > 0.05) in these series.

With regards to the distribution of MWPyV infection, considering all types of biological samples, as shown in Table 2 the infection could only be detected in the lymphoid tissues of healthy children, and more precisely in tonsils (6 %) and in adenoids (1 %). Infections were characterized by low replication rates, typically ranging from 5 to 10 viral copies/reaction. The proportion of infected cells, expressed as the number of viral copies in the cells (% of infected cells: from 0.05 to 1.0) and calculated on the basis of the copies of β-globin (range: 3 × 103 to 1 × 104copies/reaction) assuming that one copy of the viral genome infects one cell, was constantly low. No JCPyV or BKPyV co-infection was found in MWPyV positive samples, while the EBV lymphotropic reference showed a similar percentage of infection both in tonsils and adenoids (38 and 37 % respectively).
Table 2

Prevalence of Malawi and JC/BK polyomavirus and EBV infections in biological samples from healthy and autoimmune children

 

Samples

  

Polyomavirus No. (%)

 

Ref. virus No. (%)

 

Total No.

MWPyV

JCPyV

BKPyV

EBV

Healthy children

      

No. 200

Tonsil

100

6 (6 %)

0

0

38 (38 %)

 

Adenoid

100

1 (1 %)

0

0

37 (37 %)

 

Blood

100

0

0

0

12 (12 %)

 

Urine

100

0

0

0

 

Stoola

100

0

0

0

 

Total No.

500

7 (1.4 %)

0

0

Autoimmune children

      

No. 40

Blood

40

0

6 (15 %)

0

2 (5 %)

 

Urine

40

0

40 (100 %)

5 (12.5 %)

 

Total No.

80

0

46 (57.5 %)

5 (6.25 %)

a30 with acute gastrointestinal symptoms with a diagnosis of Enterovirus 10/30 and Norovirus 20/30 infections

No MWPyV DNA was detected in stool specimens from babies with gastroenteric syndrome with or without diarrhea.

With regards to autoimmune children, neither MWPyV nor BKPyV genomic sequences were detected in blood, while JCPyV viremia was observed in 15 % (6/40) of the samples (geometric mean viral load of 3.9 × 103 copies/mL) recovered from children in therapy with Infliximab. The lymphotropic EBV was also present in 5 % (2/40) of the blood samples. Urinary BKPyV shedding was observed in 12.5 % (5/40) (geometric mean viral load of 3.7 × 103 copies/mL) of the children, while JCPyV shedding was detected in 100 % of the urine samples (geometric mean viral load of 2.5 × 106copies/mL).

Discussion and conclusions

Several studies have reported the widespread distribution of MWPyV in different areas of the world, including Africa, USA, Asia, Australia and South America [25, 45, 48, 49, 52]. A recent MWPyV seroprevalence survey on the Italian general population has documented, for the first time, the circulation of this polyomavirus also in this geographic region [46].

The detection of MWPyV sequences in stool and respiratory samples from healthy children in different geographical areas, suggests that the establishment of the primary infection is likely to have taken place at an early age, and that the gastrointestinal and/or respiratory tracts may be sites of viral persistence. However, the relationship of MWPyV with immunity is poorly understood, and this can be explained by the absence of a recognizable clinical condition and of a definitive identification of the human tissues where it latently persists.

In the present study, based on the natural history of other human polyomaviruses, tonsil and adenoid biopsies and blood and urine specimens were screened in healthy and autoimmune children, to investigate possible sites of MWPyV persistence.

The results from this series, show an overall frequency of MWPyV infection of 2.9 % which increases slightly to 3.5 %, when only the cohort of healthy children is considered. The discrepancy between the virus detection rate and the high seroprevalence rate (from 26.9 % to around 52 %) found in Italian healthy children of similar age [46], suggests that MWPyV may infect a host niche that has not yet been properly identified.

The association of MWPyV with gastroenteric symptoms (e.g., diarrhea) has suggested a possible role for this virus in intestinal disorders, either acting alone or in synergy with enteric pathogens [25, 53]. For this reason, we tested stool specimens from healthy babies with diarrhea, 30 % of whom had a diagnosis of Entero- and Norovirus infections, but yielded no positive results. This contrast in data may be due to the small number of samples we analyzed (n°100) compared to the published St. Louis series (n°514), and to the low prevalence rate of infection (2.3 %) registered in that study [25]. In addition, the frequency and duration of MWPyV stool shedding after infection/reactivation has not, as yet, been established with certainty, and this may have led to an underestimation of infection in St. Louis study.

The results from this study seem to be in line with those from a recent investigation by Rockett et al. in which MWPyV was associated with upper respiratory infection symptoms in >33 % of sole detection episodes, and only rarely with gastrointestinal symptoms [49]. Moreover, in a previous Australian study by the same author, MWPyV viremia and viruria were not observed in either the healthy or the autoimmune group, indicating that there was no systemic involvement of peripheral lymphocytes [53]. Malawi DNA is more likely to be detectable in blood during the primary infection rather than during reactivation, the latter being an event that depends on the specific biological features of the virus, on local stimuli in infected tissues and on the level of immunosuppression of the host [54].

The present study shows that MWPyV can infect lymphoid cells from healthy children, although at a lower rate (7 %) than lymphotropic EBV (37.5 %) and WUPyV (34.9 %) [43], thereby supporting the hypothesis of the transient nature of these tissues as sites of infection. These data appear to be in contrast with those by Peng et al. [45], which highlighted the role of tonsils as sites of persistence also for MWPyV, despite the low rate of detection (2 %) and the likelihood oral-pharyngeal contamination during swab sampling of the mucosal surfaces of palatine tonsils.

Although previous studies have shown that different polyomavirus strains can coexist in the same organ of the same host, there is no evidence of BKPyV, JCPyV or EBV co-infection in these tissues [5557].

The association between diminished immunity and reactivation is less clear for this novel human polyomavirus. In our study, MWPyV was undetectable in the urine and in the blood of autoimmune children, while, in agreement with other published data, urinary shedding of BKPyV and JCPyV was confirmed. Moreover, JCPyV reactivation or subclinical infection was detected in the blood of 6 children treated with biological drug, confirming the risk of developing PML as a result of long-term of monoclonal therapy [5860].

In conclusion, in this series of healthy immunocompetent Italian children, no trace of MWPyV infection was found in biological samples indicated by previous studies as possible vehicles of intra-human transmission. Conversely, our data demonstrated that the secondary lymphoid tissues can actually harbour MWPyV. However, only very few cells proved to be infected suggesting that these tissues are unlikely to be the preferred site of latency, at least in this series of children.

Nevertheless, the high MWPyV seroprevalence found in young children from this geographic area, and the in vitro ability of MWPyV to bind to cellular tumor suppressor factors and to promote chronic infection [52], seem to support the hypothesis that infection/reactivation and transmission of MWPyV may have clinical consequences only in severely immunocompromised hosts. This observation warrants further investigations in organ transplant recipients and AIDS and cancer patients.

Abbreviations

BKPyV, BK polyomavirus; EBV, Epstein Barr Virus; EIA: enzyme immunoassay; HPyV12, human polyomavirus 12; JCPyV, JC polyomavirus; KIPyV, KI polyomavirus; MCPyV, Merkel cell polyomavirus; MWPyV, Malawi polyomavirus; NJPyV, New Jersey polyomavirus; PML, progressive multifocal leukoencephalopathy; PVAN, polyomavirus associated nephropathy; PyV, polyomavirus; real-time qPCR, quantitative real-time PCR; STLPyV, Saint Louis polyomavirus; TSPyV, TrichodysplasiaSpinulosa-associated polyomavirus; WUPyV, WU polyomavirus

Declarations

Funding

The study was supported by RC 11/11 from Italian Ministry of Health.

Authors’ contributions

NP, NZ and MC participated in the study design. EO contributed to collection of clinical specimens and demographic data. NP and NZ carried out the real-time PCR, performed the data analysis and drafted the manuscript. MC critically revised the manuscript for important intellectual content. AK participated in revising the manuscript for the English language. All authors have read and approved the content of this manuscript.

Competing interests

The authors declare that they have no competing interests.

Ethics approval and consent to participate

The study was approved by the Institutional Scientific Board of “Burlo Garofolo” Children’s Hospital (Trieste) and by the local Independent Ethics Committee. Parental written informed consent was obtained for each participant in accordance with the principles outlined in the Declaration of Helsinki.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Institute for Maternal and Child Health - IRCCS “Burlo Garofolo”, Trieste, Italy
(2)
Medical Sciences Department, University of Trieste, Trieste, Italy

References

  1. Jiang M, Abend JR, Johnson SF, Imperiale MJ. The role of polyomaviruses in human disease. Virology. 2009;384:266–73. doi:10.1016/j.virol.2008.09.027.View ArticlePubMedGoogle Scholar
  2. Rinaldo CH, Hirsch HH. The human polyomaviruses: from orphans and mutants to patchwork family. Acta Pathol Microbiol Immunol Scand. 2013;121:681–4. doi:10.1111/apm.12125.View ArticleGoogle Scholar
  3. Dalianis T, Hirsch HH. Human polyomaviruses in disease and cancer. Virology. 2013;437:63–72. doi:10.1016/j.virol.2012.12.015.View ArticlePubMedGoogle Scholar
  4. Mishra N, Pereira M, Rhodes RH, An P, Pipas JM, Jain K, et al. Identification of a novel polyomavirus in a pancreatic transplant recipient with retinal blindness and vasculitic myopathy. J Infect Dis. 2014;210:1595–9. doi:10.1093/infdis/jiu250.View ArticlePubMedPubMed CentralGoogle Scholar
  5. Taghavi A, Mohammadi-Torbati P, Kashi AH, Rezaee H, Vaezjalali M. Polyomavirus hominis 1 (BK virus) infection in prostatic tissues: cancer versus hyperplasia. Urol J. 2015;12:2240–4.PubMedGoogle Scholar
  6. Yin WY, Lee MC, Lai NS, Lu MC. BK virus as a potential oncovirus for bladder cancer in a renal transplant patient. J Formos Med Assoc. 2015;114:373–4. doi:10.1016/j.jfma.2012.02.019.View ArticlePubMedGoogle Scholar
  7. Eftimov T, Enchev Y, Tsekov I, Simenov P, Kalvatchev Z, Encheva E. JC polyomavirus in the aetiology and pathophysiology of glial tumours. Neurosurg Rev. 2015;39:47–53. doi:10.1007/s10143-015-0676-5.View ArticlePubMedGoogle Scholar
  8. Feng H, Shuda M, Chang Y, Moore PS. Clonal integration of a polyomavirus in human Merkel cell carcinoma. Science. 2008;319:1096–100. doi:10.1126/science.1152586.View ArticlePubMedPubMed CentralGoogle Scholar
  9. Houben R, Shuda M, Weinkam R, Schrama D, Feng H, Chang Y, et al. Merkel cell polyomavirus-infected Merkel cell carcinoma cells require expression of viral T antigens. J Virol. 2010;84:7064–72. doi:10.1128/JVI.02400-09.View ArticlePubMedPubMed CentralGoogle Scholar
  10. Feltkamp MC, Kazem S, van der Meijden E, Lauber C, Gorbalenya AE. From Stockholm to Malawi: recent developments in studying human polyomaviruses. J Gen Virol. 2013;94:482–96. doi:10.1099/vir.0.048462-0.View ArticlePubMedGoogle Scholar
  11. Sadeghi F, Ghanadan A, Salehi Vaziri M, Bokharaei Salim F, Monavari SH, Keyvani H. Merkel cell polyomavirus infection in a patient with merkel cell carcinoma: a case report. Jundishapur J Microbiol. 2015;8:e17849. doi:10.5812/jjm.17849.PubMedPubMed CentralGoogle Scholar
  12. Hirsch HH, Brennan DC, Drachenberg CB, Ginevri F, Gordon J, Limaye AP, et al. Polyomavirus-associated nephropathy in renal transplantation: interdisciplinary analyses and recommendations. Transplantation. 2015;79:1277–86.View ArticleGoogle Scholar
  13. Lipshutz GS, Mahanty H, Feng S, Hirose R, Stock PG, Kang SM, et al. BKV in simultaneous pancreas-kidney transplant recipients: a leading cause of renal graft loss in first 2 years post-transplant. Am J Transplant. 2005;5:366–73.View ArticlePubMedGoogle Scholar
  14. Mitterhofer AP, Pietropaolo V, Barile M, Tinti F, Fioriti D, Mischitelli M, et al. Meaning of early polyomavirus-BK replication post kidney transplant. Transplant Proc. 2010;42:1142–5. doi:10.1016/j.transproceed.2010.03.130.View ArticlePubMedGoogle Scholar
  15. Laskin BL, Denburg M, Furth S, Diorio D, Goebel J, Davies SM, et al. BK viremia precedes hemorrhagic cystitis in children undergoing allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2013;19:1175–82. doi:10.1016/j.bbmt.2013.05.002.View ArticlePubMedPubMed CentralGoogle Scholar
  16. Brooks BR, Walker DL. Progressive multifocal leukoencephalopathy. Neurol Clin. 1984;2:299–313.PubMedGoogle Scholar
  17. Safak M, Khalili K. An overview: human polyomavirus JC virus and its associated disorders. J Neurovirol. 2003;9 Suppl 1:3–9.View ArticlePubMedGoogle Scholar
  18. Haycox CL, Kim S, Fleckman P, Smith LT, Piepkorn M, Sundberg JP, et al. Trichodysplasia spinulosa - a newly described folliculocentric viral infection in an immunocompromised host. Investig Dermatol Symp Proc. 1999;4:268–71.View ArticleGoogle Scholar
  19. Sperling LC, Tomaszewski MM, Thomas DA. Viral-associated trichodysplasia in patients who are immunocompromised. J Am Acad Dermatol. 2004;50:318–22.View ArticlePubMedGoogle Scholar
  20. Van der Meijden E, Janssens RW, Lauber C, Bouwes Bavinck JN, Gorbalenya AE, Feltkamp MC. Discovery of a new human polyomavirus associated with trichodysplasiaspinulosa in an immunocompromized patient. PLoS Pathog. 2010;6, e1001024. doi:10.1371/journal.ppat.1001024.View ArticlePubMedPubMed CentralGoogle Scholar
  21. Gaynor AM, Nissen MD, Whiley DM, Mackay IM, Lambert SB, Wu G, et al. Identification of a novel polyomavirus from patients with acute respiratory tract infections. PLoS Pathog. 2007;3, e64.View ArticlePubMedPubMed CentralGoogle Scholar
  22. Allander T, Andreasson K, Gupta S, Bjerkner A, Bogdanovic G, Persson MA, et al. Identification of a third human polyomavirus. J Virol. 2007;81:4130–6.View ArticlePubMedPubMed CentralGoogle Scholar
  23. Csoma E, Mészáros B, Asztalos L, Gergely L. WU and KI polyomaviruses in respiratory, blood and urine samples from renal transplant patients. J Clin Virol. 2015;64:28–33. doi:10.1016/j.jcv.2014.12.020.View ArticlePubMedGoogle Scholar
  24. Iaria M, Caccuri F, Apostoli P, Giagulli C, Pelucchi F, Padoan RF, et al. Detection of KI WU and Merkel cell polyomavirus in respiratory tract of cystic fibrosis patients. Clin Microbiol Infect. 2015;603:e9–15. doi:10.1016/j.cmi.2015.01.025.Google Scholar
  25. Siebrasse EA, Reyes A, Lim ES, Zhao G, Mkakosya RS, Manary MJ, et al. Identification of MW polyomavirus, a novel polyomavirus in human stool. J Virol. 2012;86:10321–6. doi:10.1128/JVI.01210-12.View ArticlePubMedPubMed CentralGoogle Scholar
  26. Lim ES, Reyes A, Antonio M, Saha D, Ikumapayi UN, Adeyemi M, et al. Discovery of STL polyomavirus, a polyomavirus of ancestral recombinant origin that encodes a unique T antigen by alternative splicing. Virology. 2013;436:295–303. doi:10.1016/j.virol.2012.12.005.View ArticlePubMedGoogle Scholar
  27. Korup S, Rietscher J, Calvignac-Spencer S, Trusch F, Hofmann J, Moens U, et al. Identification of a novel human polyomavirus in organs of the gastrointestinal tract. PLoS One. 2013;8, e58021. doi:10.1371/journal.pone.0058021.View ArticlePubMedPubMed CentralGoogle Scholar
  28. Ramqvist T, Nordfors C, Dalianis T, Ragnarsson-Olding B. DNA from human polyomaviruses, TSPyV, MWPyV, HPyV6, 7 and 9 was not detected in primary mucosal melanomas. Anticancer Res. 2014;34:639–43.PubMedGoogle Scholar
  29. Kean JM, Rao S, Wang M, Garcea RL. Seroepidemiology of human polyomaviruses. PLoS Pathog. 2009;5, e1000363. doi:10.1371/journal.ppat.1000363.View ArticlePubMedPubMed CentralGoogle Scholar
  30. Antonsson A, Green AC, Mallitt KA, O’Rourke PK, Pawlita M, Waterboer T, et al. Prevalence and stability of antibodies to the BK and JC polyomaviruses: a long-term longitudinal study of Australians. J Gen Virol. 2010;91:1849–53. doi:10.1099/vir.0.020115-0.View ArticlePubMedGoogle Scholar
  31. Nicol JT, Robinot R, Carpentier A, Carandina G, Mazzoni E, Tognon M, et al. Age-specific seroprevalences of merkel cell polyomavirus, human polyomaviruses 6, 7, and 9, and trichodysplasia spinulosa-associated polyomavirus. Clin Vaccine Immunol. 2013;20:363–8. doi:10.1128/CVI.00438-12.View ArticlePubMedPubMed CentralGoogle Scholar
  32. Bennett SM, Broekema NM, Imperiale MJ. BK polyomavirus: emerging pathogen. Microbes Infect. 2012;14:672–83. doi:10.1016/j.micinf.2012.02.002.View ArticlePubMedPubMed CentralGoogle Scholar
  33. Zanotta N, Delbue S, Rossi T, Pelos G, D’Agaro P, Monasta L, et al. Molecular epidemiology of JCV genotypes in patients and healthy subjects from Northern Italy. J Med Virol. 2013;85:1286–92. doi:10.1002/jmv.23585.View ArticlePubMedGoogle Scholar
  34. De Gascun CF, Carr MJ. Human polyomavirus reactivation: disease pathogenesis and treatment approaches. Clin Dev Immunol. 2013;2013:373579. doi:10.1155/2013/373579.View ArticlePubMedPubMed CentralGoogle Scholar
  35. Vanchiere JA, Roger K, Nicome RK, Greer JM, Demmler GJ, Butel JS. Frequent detection of polyomaviruses in stool samples from hospitalized children. J Infect Dis. 2005;192:658–64.View ArticlePubMedPubMed CentralGoogle Scholar
  36. Kato A, Kitamura T, Takasaka T, Tominaga T, Ishikawa A, Zheng HY, et al. Detection of the archetypal regulatory region of JC virus from the tonsil tissue of patients with tonsillitis and tonsilar hypertrophy. J Neurovirol. 2004;10:244–9.View ArticlePubMedGoogle Scholar
  37. Comar M, Zanotta N, Bovenzi M, Campello C. JCV/BKV and SV40 viral load in lymphoid tissues of young immunocompetent children from an area of north-east Italy. J Med Virol. 2010;82:1236–40. doi:10.1002/jmv.21786.View ArticlePubMedGoogle Scholar
  38. Khalili K, Del Valle L, Otte J, Weaver M, Gordon J. Human neurotropic polyomavirus, JCV, and its role in carcinogenesis. Oncogene. 2003;22:5181–91.View ArticlePubMedGoogle Scholar
  39. Delbue S, Pagani E, Guerini FR, Agliardi C, Mancuso R, Borghi E, et al. Distribution, characterization and significance of polyomavirus genomic sequences in tumors of the brain and its covering. J Med Virol. 2005;77:447–54.View ArticlePubMedGoogle Scholar
  40. Delbue S, Elia F, Carloni C, Tavazzi E, Marchioni E, Carluccio S, et al. JC virus load in cerebrospinal fluid and transcriptional control region rearrangements may predict the clinical course of progressive multifocal leukoencephalopathy. J Cell Physiol. 2012;227:3511–7. doi:10.1002/jcp.24051.View ArticlePubMedPubMed CentralGoogle Scholar
  41. Wollebo HS, White MK, Gordon J, Berger JR, Khalili K. Persistence and pathogenesis of the neurotropic polyomavirus JC. Ann Neurol. 2015;77:560–70. doi:10.1002/ana.24371.View ArticlePubMedPubMed CentralGoogle Scholar
  42. Babakir-Mina M, Ciccozzi M, Bonifacio D, Bergallo M, Costa C, Cavallo R, et al. Identification of the novel KI and WU polyomaviruses in human tonsils. J Clin Virol. 2009;46:75–9. doi:10.1016/j.jcv.2009.06.009.View ArticlePubMedGoogle Scholar
  43. Comar M, Zanotta N, Rossi T, Pelos G, D’Agaro P. Secondary lymphoid tissue as an important site for WU polyomavirus infection in immunocompetent children. J Med Virol. 2011;83:1446–50. doi:10.1002/jmv.22124.View ArticlePubMedGoogle Scholar
  44. Sadeghi M, Aaltonen LM, Hedman L, Chen T, Söderlund-Venermo M, Hedman K. Detection of TS polyomavirus DNA in tonsillar tissues of children and adults: evidence for site of viral latency. J Clin Virol. 2014;59:55–8. doi:10.1016/j.jcv.2013.11.008.View ArticlePubMedGoogle Scholar
  45. Peng J, Li K, Zhang C, Jin Q. MW polyomavirus and STL polyomavirus present in tonsillar tissues from children with chronic tonsillar disease. Clin Microbiol Infect. 2015;22:97. doi:10.1016/j.cmi.2015.08.028.PubMedGoogle Scholar
  46. Nicol JT, Leblond V, Arnold F, Guerra G, Mazzoni E, Tognon M, et al. Seroprevalence of human Malawi polyomavirus. J Clin Microbiol. 2014;52:321–3. doi:10.1128/JCM.02730-13.View ArticlePubMedPubMed CentralGoogle Scholar
  47. Yu G, Greninger AL, Isa P, Phan TG, Martínez MA, de la Luz SM, et al. Discovery of a novel polyomavirus in acute diarrheal samples from children. PLoS One. 2012;7, e49449. doi:10.1371/journal.pone.0049449.View ArticlePubMedPubMed CentralGoogle Scholar
  48. Torres C, Barrios ME, Cammarata RV, Cisterna DM, Estrada T, Martini Novas S, et al. High diversity of human polyomaviruses in environmental and clinical samples in Argentina: detection of JC, BK, Merkel-cell, Malawi, and human 6 and 7 polyomaviruses. Sci Total Environ. 2016;542:92–202. doi:10.1016/j.scitotenv.2015.10.047.View ArticleGoogle Scholar
  49. Rockett RJ, Bialasiewicz S, Mhango L, Gaydon J, Holding R, Whiley DM, et al. Acquisition of human polyomaviruses in the first 18 months of life. Emerg Infect Dis. 2015;21:365–7. doi:10.3201/eid2102.141429.View ArticlePubMedPubMed CentralGoogle Scholar
  50. Brodsky L. Modern assessment of tonsils and adenoids. Pediatr Clin North Am. 1989;36:1551–69.PubMedGoogle Scholar
  51. Comar M, Zanotta N, Del Savio R, Vascotto F, Calabrese N, Zorat F, et al. No evidence of polyomavirus and EBV infections in Italian patients with mixed cryoglobulinemia infected chronically with HCV. J Med Virol. 2014;86:666–71. doi:10.1002/jmv.23867.View ArticlePubMedGoogle Scholar
  52. Berrios C, Jung J, Primi B, Wang M, Pedamallu C, Duke F, et al. Malawi polyomavirus is a prevalent human virus that interacts with known tumor suppressors. J Virol. 2015;89:857–62. doi:10.1128/JVI.02328-14.View ArticlePubMedGoogle Scholar
  53. Rockett RJ, Sloots TP, Bowes S, O’Neill N, Ye S, Robson J, et al. Detection of novel polyomaviruses, TSPyV, HPyV6, HPyV7, HPyV9 and MWPyV in feces, urine, blood, respiratory swabs and cerebrospinal fluid. PLoS One. 2013;8, e62764. doi:10.1371/journal.pone.0062764.View ArticlePubMedPubMed CentralGoogle Scholar
  54. Ling PD, Lednicky JA, Keitel WA, Poston DG, White ZS, Peng R, et al. The dynamics of herpesvirus and polyomavirus reactivation and shedding in healthy adults: a 14-month longitudinal study. J Infect Dis. 2003;187:1571–80.View ArticlePubMedGoogle Scholar
  55. Boldorini R, Veggiani C, Barco D, Monga G. Kidney and urinary tract polyomavirus infection and distribution: molecular biology investigation of 10 consecutive autopsies. Arch Pathol Lab Med. 2005;129:69–73.PubMedGoogle Scholar
  56. Schowalter RM, Pastrana DV, Pumphrey KA, Moyer AL, Buck CB. Merkel cell polyomavirus and two previously unknown polyomaviruses are chronically shed from human skin. Cell Host Microbe. 2010;7:509–15. doi:10.1016/j.chom.2010.05.006.View ArticlePubMedPubMed CentralGoogle Scholar
  57. Liaw YC, Chen CH, Shu KH, Fang CY, Ou WC, Chen PL, et al. Recombined sequences between the non-coding control regions of JC and BK viruses found in the urine of a renal transplantation patient. Virus Genes. 2012;45:581–4. doi:10.1007/s11262-012-0815-9.View ArticlePubMedGoogle Scholar
  58. Kwak EJ, Vilchez RA, Randhawa P, Shapiro R, Butel JS, Kusne S. Pathogenesis and management of polyomavirus infection in transplant recipients. Clin Infect Dis. 2002;35:1081–7.View ArticlePubMedGoogle Scholar
  59. Bellizzi A, Nardis C, Anzivino E, Rodìo D, Fioriti D, Mischitelli M, et al. Human polyomavirus JC reactivation and pathogenetic mechanisms of progressive multifocal leukoencephalopathy and cancer in the era of monoclonal antibody therapies. J Neurovirol. 2012;18:1–11. doi:10.1007/s13365-012-0080-7.View ArticlePubMedGoogle Scholar
  60. Delbue S, Elia F, Carloni C, Pecchenini V, Franciotta D, Gastaldi M, et al. JC virus urinary excretion and seroprevalence in natalizumab-treated multiple sclerosis patients. J Neurovirol. 2015;21:645–52. doi:10.1007/s13365-014-0268-0.View ArticlePubMedGoogle Scholar

Copyright

© The Author(s). 2016

Advertisement